Nucs AI was born from a critical realization: the growing demand for cancer diagnostics was colliding with limited radiologist capacity, creating a crisis in healthcare. The founders - oncologists, AI researchers, and healthcare innovators - saw firsthand how manual, time-consuming processes for analyzing PSMA-PET/CT scans were creating bottlenecks in patient care. They recognized that even as imaging technology advanced, the tools to interpret it efficiently weren't keeping pace. Radiologists were burning out, patients were waiting longer for results, and critical treatment decisions were delayed.
So they built Nucs AI - a comprehensive AI platform that automates the detection, staging, and treatment response evaluation of prostate cancer. The company's suite of solutions (DeepPSMA, SelectPSMA, and TrackPSMA) delivers 92% accuracy in identifying PSMA-positive lesions, processes scans in under a minute, and eliminates manual work in over 50% of cases. Headquartered in San Francisco with roots in Berlin, Nucs AI has raised $3.5M in seed funding to advance its mission of empowering clinicians with faster, more precise diagnostic tools. The company isn't just building software - it's redefining how AI and imaging work together to improve patient outcomes.
